Garuda - Garba Rujukan Digital

Indriani R

Unknown Affiliation

Author-ID : 353279

Veterinary

Published : 3 Documents Claim Missing Document

Claim Missing Document

Articles

Efficacy of application of vaccine AI H5N1 clade 2.1.3 on Mojosari ducks challenge against AI H5N1 clade 2.3.2 in laboratory conditions R, Indriani; NLPI, Dharmayanti; R.M.A., Adjid
Indonesian Journal of Animal and Veterinary Sciences Vol 19, No 1 (2014)
Publisher : Indonesian Animal Sciences Society

Influenza virus HPAI H5N1 clade 2.3.2 outbreaks since September 2012 caused high mortality in ducks. Vaccination is one of strategies recommended by government. However, AI H5N1 clade 2.3.2 vaccine not yet available during this research, while AI H5N1 clade 2.1.3 vaccines available in markets. Therefore it was important to do study on efficay of HPAI H5N1 clade 2.1.3. vaccines on duck at laboratory scale. Three groups of Mojosari duck were used in this study, they were 1 group vaccinated with A Vaccine, 1 group vaccinated with B Vaccine, and 1 group as control (not vaccinated). Vacination groups consisted of 9 DOD and control group was consisted of 6 DOD. Vaccination was conducted when the duck at three weeks old of age using single dose recommended by producer. At three weeks later (ducks at 6 weeks old of age) all Groups of ducks were challenged with virus HPAI H5N1 clade 2.3.2 at dose 106 EID50/ml by drops intranasaly. Result showed that Group 1 (vaccinated with A Vaccine) produced 67% protection (3 out of 9 ducks died), Group 2 (vaccinated with B Vaccine) produced 100% protection (non out of 9 ducks died), and Group 3 (control, not vaccinated) produce 0% protection (all of 9 ducks died). This study give an alternative of choise to use AI H5N1 Clade 2.1.3 vaccine with high protection when AI H5N1 Clade 2.3.2 vaccine not available in markets to controll high mortality in ducks caused by HPAI H5N1 clade 2.3.2 outbreaks. Key Words: Duck, HPAI, AI, Avian Influenza, Vaccine

Protection level of AI H5N1 vaccine clade 2.1.3 commercial against AI H5N1 clade 2.3.2 virus from Ducks to SPF chicken in laboratory conditions Indriani R; Dharmayanti NLPI
Jurnal Ilmu Ternak dan Veteriner Vol 20, No 1 (2015): MARCH 2015
Publisher : Indonesian Center for Animal Research and Development (ICARD)

Highly Pathogenic Avian Influenza (HPAI) subtype H5N1 clade 2.3.2 has infected chickens in farms, causing mortality and a decrease in egg production. Vaccination is one of the strategies to control disease of AI subtype H5N1. AI H5N1 clade 2.1.3 vaccine is available commercially. The effectiveness of two vaccines of AI H5N1 clade 2.1.3 (product A and B), and AI H5N1 clade 2.3.2 (Sukoharjo) against AI H5N1 clade 2.3.2 (Sukoharjo) virus SPF chickens was tested in laboratory. Four groups of SPF chickens were used in this study, there were (1) vaccinated with H5N1 clade 2.1.3 (product A), (2) vaccinated with H5N1 clade 2.1.3 (product B), (3) vaccinated with AI H5N1 clade 2.3.2 and (4) unvaccinated (as a control). Each vaccinated group consisted of 10 chicken except 8 chicken for control group. SPF chicken were vaccinated with 1 dose of vaccine at 3 weeks olds, and then after 3 weeks post vaccination (at 6 weeks olds). All group of chicken were challenged with 106 EID50 per 0.1 ml via intranasal. The results showed, chicken vaccinated with H5N1 clade 2.1.3 product A and B gave 100 and 80% protection respectively, but showed challenged virus shedding, whereas vaccine of H5N1 clade 2.3.2 gave 100% protection from mortality and without virus shedding. Vaccines of AI H5N1 clade 2.1.3 product A was better than vaccine product B, and when chicken vaccinated against H5N1 clade 2.3.2, H5N1 clade 2.3.2 vaccine was the best to be used. In order to protect chicken from AI subtype H5N1 clade 2.1.3 and 2.3.2 in the field, a bivalent vaccine of H5N1 clade 2.1.3 and 2.3.2 subtypes should be developed.

Efficacy of application of vaccine AI H5N1 clade 2.1.3 on Mojosari ducks challenge against AI H5N1 clade 2.3.2 in laboratory conditions Indriani R; Dharmayanti NLPI; Adjid R.M.A.
Jurnal Ilmu Ternak dan Veteriner Vol 19, No 1 (2014): MARCH 2014
Publisher : Indonesian Center for Animal Research and Development (ICARD)

Influenza virus HPAI H5N1 clade 2.3.2 outbreaks since September 2012 caused high mortality in ducks. Vaccination is one of strategies recommended by government. However, AI H5N1 clade 2.3.2 vaccine not yet available during this research, while AI H5N1 clade 2.1.3 vaccines available in markets. Therefore it was important to do study on efficay of HPAI H5N1 clade 2.1.3. vaccines on duck at laboratory scale. Three groups of Mojosari duck were used in this study, they were 1 group vaccinated with A Vaccine, 1 group vaccinated with B Vaccine, and 1 group as control (not vaccinated). Vacination groups consisted of 9 DOD and control group was consisted of 6 DOD. Vaccination was conducted when the duck at three weeks old of age using single dose recommended by producer. At three weeks later (ducks at 6 weeks old of age) all Groups of ducks were challenged with virus HPAI H5N1 clade 2.3.2 at dose 106 EID50/ml by drops intranasaly. Result showed that Group 1 (vaccinated with A Vaccine) produced 67% protection (3 out of 9 ducks died), Group 2 (vaccinated with B Vaccine) produced 100% protection (non out of 9 ducks died), and Group 3 (control, not vaccinated) produce 0% protection (all of 9 ducks died). This study give an alternative of choise to use AI H5N1 Clade 2.1.3 vaccine with high protection when AI H5N1 Clade 2.3.2 vaccine not available in markets to controll high mortality in ducks caused by HPAI H5N1 clade 2.3.2 outbreaks. Key Words: Duck, HPAI, AI, Avian Influenza, Vaccine

Title

Found 3 Documents
Search

Abstract

Abstract

Abstract

Title Search

Found 3 Documents Search

Abstract

Abstract

Abstract

Title

Found 3 Documents
Search